Nonclinical Toxicology

General Toxicology Testing

General toxicology is a branch of science that deals with the study of adverse effects that chemicals, pharmaceutical products, or other agents may have on living organisms. Its main goal is to identify, characterize, and quantify these effects, evaluating the relationship between the administered dose and the observed toxic response. This field is essential in the development of new drugs, as it helps determine the safety of compounds before their use in humans, ensuring compliance with regulatory and ethical standards. 

Preclinical regulatory CRO

Scroll down

Established – 2000

In general toxicology studies, animal models are used to evaluate a wide of parameters, including as acute, subacute, subchronic, and chronic toxicity. These studies involve the monitoring of clinical signs, detailed observations, behavior, body weight, food consumption, organ function, as well as histopathological, clinical pathology assessments, and toxicokinetic analysis. When applicable, additional recovery groups are included to assess the reversibility of observed effects. The data collected not only helps identify potential health risks, but also supports the determination of safe and tolerable dose levels, providing a robust foundation for subsequents clinical development.

General Toxicology Testing

What services we offer

Our general toxicoogy platform includes a full range of study types, adapted to the specific development stage of each compound:

Dose Range Finding (DRF) & Maximum Tolerated Dose (MTD)

These exploratory non-GLP studies are essential for determining the appropiate dose levels for subsequents regulatory toxicologies studies. They help identify the maximum tolerated dose and potential target organs, guiding the design of GLP-compliant studies.

Dose Range Finding (DRF) & Maximum Tolerated Dose (MTD)
Repeated Dose Toxicity Studies

Repeated Dose Toxicity Studies

Conducted under GLP, these studies assess the effects of repeated exposure over a defined period – typically 14, 28, 90 or 180 days – helping to define the No Observed Adverse Effect Level (NOAEL) and other key toxicological endpoints. These studies are mandatory for dossier submissions across multiple industries. 

Updates

If you are looking for a committed team,
with experience and scientific vision,
Vivotecnia is your ally in preclinical
toxicology.

We use cookies

We use cookies to improve your experience on this website. You may choose which types of cookies to allow and change your preferences at any time. Disabling cookies may impact your experience on this website. You can learn more by viewing our Cookie Policy.